HCC
Conditions
Interventions
B:TACE+nimotuzumab
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: >= 18 years, <= 75 years; 2. HCC was diagnosed clinically or pathologically; 3. Complete clinical, laboratory and imaging data; 4. Liver tumor burden < 70%(tumor volume in the whole liver), no main portal vein tumor thrombus or although there is a main tumor thrombus, but the collateral branch is well established; 5. IIb-IIIb stages of liver cancer by CNLC; 6. Child-Pugh grade A or B; 7. ECOG-PS score: 0-2; 8. There are no other contraindications to angiography (e.g. contrast allergy, uncontrolled infection, uncorrectable coagulation skills, etc.); 9. There are no contraindications to the use of PD-1 (e. g. autoimmune diseases, history of organ transplantation, etc.); 10. The subjects voluntarily joined the study, signed the informed consent, and were able to cooperate with the follow-up and complete the study project.
Exclusion criteria
Exclusion criteria: 1. ECOG-PS score >= 2; 2. Child- Pugh grade C; 3. Abnormal coagulation function (INR> 1.5 or prothrombin time (PT)> ULN 4 seconds), with bleeding tendency or receiving thrombolytic or anticoagulant therapy; 4. the presence of grade II or more myelosuppression; 5. active period of infectious diseases; 6. Those who have severe heart, lung, kidney, brain and other basic diseases and cannot tolerate interventional therapy; 7. Those who cannot tolerate a complete treatment cycle (>= 2 times) and cannot objectively evaluate the efficacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Size; | — |
Countries
Chian
Contacts
Public ContactMao Qiang Wang
Outcome results
None listed